New drug cocktail aims to boost lymphoma remission

This study tests whether adding zanubrutinib to the standard R2 regimen (rituximab and lenalidomide) improves outcomes for adults with newly diagnosed follicular lymphoma. About 100 participants will be randomly assigned to receive either the new ZR2 combo or standard R2, followed by maintenance therapy. The main goal is to see if more patients achieve complete remission with the new combination.